Following U.S. Stocks are among the “Top Gainers” during Tuesday’s Morning Trade: Bacterin International Holdings, Inc. (NYSE:BONE), Medovex Corp. (NASDAQ:MDVX)
Their insights are depicted underneath:
Bacterin International Holdings, Inc. (NYSE:BONE), jumped nearly 19.77% and is now trading at $4.24.
NEWS Behind This JUMP:
Bacterin International Holdings, Inc. (BONE), a leader in the development of bone graft material, declared it has signed a national distribution contract with Spartan Medical, Inc., a service-disabled, veteran-owned, small business focused on distribution to government medical facilities.
Under the contract, Spartan Medical will distribute Bacterin’s proprietary product portfolio to the medical centers associated with the US Department of Defense (DOD) and the US Department of Veteran’s Affairs (VA). Spartan Medical is an established distribution entity that provides best-in-class products and services to its customers, with specific experience in orthopedic and biologics distribution, and government contracting.
Spartan Medical Inc. was founded in 2008 by a former Air Force Intelligence Officer in an effort to provide an extensive armamentarium of advanced medical devices and technologies focused on the needs of the VA and DoD Surgeon.
Bacterin International Holdings, Inc. (BONE) develops, manufactures and markets biologic products to domestic and international markets. These products are used in a variety of applications counting enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and sub-chondral repair in knee and other joint surgeries.
Medovex Corp. (NASDAQ:MDVX), inclined nearly 10.23% and is now trading at $4.85, hitting new 52-week high of $5.35, soon after a developer of medical technology products, declared that it has reached a definitive merger contract to attain 100% of the stock of Streamline, Inc., a Minneapolis, Minnesota based medical technology corporation. Closing of the merger is subject to customary conditions and approval by Streamline shareholders at a meeting planned for March 25, 2015.
Medovex anticipates to combine Streamline’s expertise in patient safety oriented durable medical equipment with Medovex’s vision for acquiring and developing medical technology that solves noteworthy challenges faced by health care providers. Streamline developed the IV Suspension System (ISS™), a patient equipment administration device that makes the administration of patients and their equipment easier, safer and more efficient within hospitals by combining the advantages of both stand-alone and bed-mounted IV pole in one system.
Jarrett Gorlin, CEO of Medovex, stated, “Pending approval, Streamline will be our first merger. According to Critical Care Medicine, there are roughly 100,000 critical care beds in U.S. hospitals. It is a turnkey attainment and its product can right away be brought to market in scale. The technology is patent protected, FDA cleared, already manufactured and extensively tested. We anticipate forming a U.S. marketing partnership in forthcoming weeks followed by a full scale product launch.”
Current methods of intra-hospital transportation require cumbersome handling and control of patient beds and mobile IV stands during the transport process. It’s during these transports that patient care can be compromised. The ISS also provides safety benefits to patients through reduction in IV line pull incidents.
Medovex was formed to attain and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection comprise those products with potential for noteworthy improvement in the quality of patient care combined with cost effectiveness. Medovex’s first pipeline product, the DenerveX™ device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than presently accessible options.
